# How PT-141 Works: Mechanism, Trial Evidence, and FDA Approval Status > PT-141 (bremelanotide) works centrally on melanocortin MC4R/MC3R receptors. A cited reading of the mechanism, the RECONNECT Phase 3 trials, the brain-imaging data, and the precise FDA approval scope. A central melanocortin mechanism, two Phase 3 trials, a brain-imaging study, and an approval that covers one indication — read in order and cited to source. ## In plain English This page covers how PT-141 works and what the studies found. The one-paragraph version: PT-141 (the research name for bremelanotide) acts on switches in the brain — melanocortin MC4R/MC3R receptors — that influence sexual desire, rather than on the blood vessels the way erectile pills do. In large trials it raised desire and lowered desire-related distress in premenopausal women with low desire, by a real but small amount. It is FDA-approved for that group only. Everything below adds the detail, with each number tied to the study it came from. ## How does PT-141 work? By agonizing melanocortin MC4R (and secondarily MC3R) receptors in hypothalamic circuits — the medial preoptic area among them — and engaging dopamine signaling linked to sexual desire [1][2]. It is a central mechanism, not a vascular one. Systemic dosing produced erections in rats and nonhuman primates and activated hypothalamic neurons (a marker called c-Fos rose), and produced rapid, dose-dependent erectile activity in men with erectile dysfunction in early work [1]. The site of action is the nervous system; the readout is desire and arousal, not blood flow. The receptors themselves are part of a family of five (MC1R through MC5R) that respond to melanocortin peptides such as alpha-MSH. PT-141 is selective for the central MC3R/MC4R subtypes, which is why its effects center on desire and appetite rather than on pigment or adrenal function. The fuller picture sits in the cards below. ## What receptors does PT-141 act on? Chiefly the melanocortin 4 receptor (MC4R) and, secondarily, the melanocortin 3 receptor (MC3R), both concentrated in the central nervous system [1]. MC4R in hypothalamic desire circuits is the principal target; the same receptor sits in appetite circuits, which is why caloric-intake and weight effects appear at high-frequency dosing [6]. A 2025 female-Syrian-hamster study found MC3R/MC4R mRNA concentrated in ventral-tegmental-area dopamine neurons, but reported that bremelanotide did not change melanocortin-receptor mRNA there and did not enhance sexual reward in a place-preference test — a careful, partly negative result suggesting the molecule does not act on that particular reward circuit [12]. ## What the research describes as PT-141's benefits The benefit, as the trials measured it, is an increase in sexual desire and a reduction in the distress that low desire causes — in the approved population, and to a modest degree. In the integrated RECONNECT Phase 3 data, bremelanotide 1.75 mg subcutaneous as-needed produced an FSFI-desire change of +0.35 (P<.001) and an FSDS-DAO item-13 change of -0.33 (P<.001) versus placebo across 24 weeks [3]. Both coprimary endpoints were met in both identical trials. The honest reading is that these effects are statistically real and clinically small, and independent re-analyses have argued exactly that — questioning the clinical meaningfulness of changes of this size and the choice of outcome measures. A 2025 conference abstract reported positive effects on female sexual arousal and orgasm beyond the desire endpoints [14], and a separate 2025 abstract set bremelanotide beside flibanserin (the other approved HSDD medication) and testosterone therapy in a comparative analysis [15]. Conference abstracts sit a tier below peer-reviewed full text, and we flag them as such. The benefit is not a guaranteed outcome for any individual; it is a group-level, trial-measured signal. ## What is a melanocortin receptor agonist? A molecule that switches on one or more of the five melanocortin receptors (MC1R-MC5R). PT-141 targets the central MC3R/MC4R subtypes, which influence sexual desire and appetite [1]. A class review situated bremelanotide within this melanocortin family as a treatment approach for male and female sexual dysfunction [8], and the receptor pharmacology is what makes the molecule's effects both central and, at MC1R, pigment-related on repeated dosing. ## The RECONNECT Phase 3 trials and the long-term extension The approval rests on [the RECONNECT Phase 3 trials](/references) — two identical randomized, double-blind, placebo-controlled studies (studies 301 and 302), 1,267 premenopausal women with HSDD, bremelanotide 1.75 mg subcutaneous as-needed over 24 weeks [3]. The coprimary desire and distress endpoints were met in both. The most common adverse events were nausea, flushing, and headache [3]. The record did not stop at 24 weeks. A 52-week open-label extension enrolled 684 women, found no new safety signals, and saw the desire improvements sustained [4]. That extension is also where the tolerability picture sharpened: the most common drug-related treatment-emergent adverse events were nausea (40.4%), flushing (20.6%), and headache (12.0%) [4]. Nausea was the principal tolerability issue and a notable reason participants stopped — a fact we carry forward, in full, on the [PT-141 side effects](/side-effects) page. ## Mechanistic brain imaging: MC4R and the desire circuit The clearest mechanistic human evidence comes from functional MRI. In a randomized, double-blind, placebo-controlled crossover study of 31 premenopausal women with HSDD, MC4R agonism significantly increased sexual desire for up to 24 hours and altered task-based brain processing of erotic stimuli — enhancing amygdala-insula functional connectivity and cerebellar and supplementary-motor activity [5]. This is direct evidence that the molecule modulates central sexual processing, consistent with the receptor pharmacology and distinct from any peripheral blood-flow account. ## Is PT-141 FDA-approved, and for whom? Yes — narrowly. Bremelanotide injection received FDA approval in June 2019 (NDA 210557) for acquired, generalized hypoactive sexual desire disorder in premenopausal women, and for no other indication [6][11]. The approved regimen is 1.75 mg subcutaneously, as needed [6]. Men, postmenopausal women, and sexual-performance use are off-label — not supported by the approval. The [FDA approval status](/references) is the single most misstated fact about PT-141, so we state it precisely: one molecule, one approved indication, one approved population. The male and erectile evidence is early-phase and investigational; the [PT-141 for men](/pt-141-for-men) page reads it on those terms. --- A sage-margined field notebook on the PT-141 (bremelanotide) record — the one approved indication, the modest measured benefit, and the nausea-led tolerability cost noticed first and cited to source, while the central-versus-peripheral mechanism is drawn plainly and the unverified field reports are penned in their own ruled margin; no clinic behind the notebook and nothing here dosed, dispensed, or sold.